The unique combination of expertise in both Fish Physiology and Molecular
Cell Biology makes ZF-screens distinctive in this expanding market

ZF-pharma has developed patented technology for the automated in vivo high-throughput screening of pharmaceutical drug candidates against diseases. This is achieved through novel robotic screens using model systems such as zebrafish. We seek industrial partners that are interested in obtaining a license for this technology or, alternatively, would prefer to outsource screening of TB drugs to ZF-pharma.

NewCatch BV has developed a tool for use in sustainable aquaculture. The tool will first be used for reproduction of the highly valued fish species eel, pikeperch and sole. We seek industrial/aquaculture partners interested in obtaining a license for ZF-implants in other fish species.

NewCatch BV carries out fish reproductive research, for instance European eel (Anguilla anguilla), exploring maturation and reproduction. ZF-screens has its own research facilities to study reproductive biology in several fish species.

ZF-Genomics offers multiple Illumina services, including mRNAseq and microRNA analysis and de novo and reference genome assemblies.

ZF-Genomics is a department of ZF-Screens BV, which uses Next generation sequencing technology to support the core business activities of our daughter companies ZF-Pharma BV and NewCatch BV. In addition, we perform Next generation sequencing tasks for (inter)national research project partners and for external customers.